Skip to content

Cannabinoids & Terpenes: NLRP3 Modulation, Gout Relevance, and EPI Applications

Cannabis produces two broad classes of bioactive compounds relevant to Open Enzyme's targets: cannabinoids (CBD, THC, CBG, CBC, THCV) and terpenes (beta-caryophyllene, limonene, myrcene, alpha-pinene, linalool). This page synthesizes what the literature actually supports, where the evidence is thin, and how these compounds fit the existing NLRP3 and gout framework.

Bottom line up front: Beta-caryophyllene is the standout compound — it has direct MSU (gout) animal model data that the inhibitor screen missed. CBD has functional NLRP3 data but no gout-specific model testing, and its mechanism is upstream (P2X7) rather than direct NLRP3 binding. CBG and THCV have newer data worth tracking. Myrcene has analgesic data in arthritis but no NLRP3 assays.

Species-gap caveat (methodological standard, 2026-04-23): Rodent cellular IC50 values for NLRP3 inhibitors routinely diverge from human cellular IC50 by up to 3 orders of magnitude. Example: dapansutrile IC50 = 1 nM in mouse J774A.1 cells vs. 1,000 nM (1 μM) in human MDM cells under LPS+nigericin stimulation (ChEMBL v34, 2026-04-23). Every rodent-derived IC50 in this document should be read with that translation uncertainty in mind — mouse efficacy is still the best preclinical gout predictor we have, but dose translation requires a species-bridging measurement (e.g., a human THP-1 IC50) before making dosing claims. (source: chembl-cross-check.md)

1. Cannabinoids and NLRP3 Inflammasome Modulation

CBD (Cannabidiol)

CBD is the most studied cannabinoid for anti-inflammatory effects outside the psychoactive pathway.

Mechanism — what's actually known:

CBD does NOT directly bind NLRP3 or ASC. The mechanism is upstream, primarily via P2X7 receptor modulation and NF-kB inhibition.

  • P2X7 modulation (in vitro): CBD (10 μM) reduced nigericin-induced K+ efflux by 13.7-13.0% in human THP-1 monocytes. Computational docking identifies CBD binding interactions with GLU172 and VAL173 residues on P2X7. K+ efflux is the canonical signal 2 trigger for NLRP3 assembly. Blocking it upstream prevents inflammasome formation without direct NLRP3 engagement (Liu et al., J Nat Prod 2020, PMID: 32374168).
  • NF-κB inhibition: Multiple in vitro studies report CBD blocks nuclear translocation of NF-κB in macrophages, reducing NLRP3 gene expression at the transcriptional level (CP1 — priming block).
  • Functional NLRP3 suppression: CBD at 0.1, 1, and 10 μM reduced IL-1β secretion in LPS-nigericin-stimulated THP-1 monocytes by 63.9%, 64.1%, and 83.1%, respectively. The 83.1% reduction at 10 μM is noted as "comparable to MCC950 and oridonin" in the same assay system (in vitro). Interpret cautiously — this comparison is assay-specific and the IC50 context differs from benchmark measurements.

No formal IC50 for NLRP3 inhibition has been reported for CBD. The functional data suggests activity in the 0.1–10 μM range, putting it in roughly the same neighborhood as quercetin (~11 μM) rather than MCC950 (7.5 nM) or oridonin (nM–low μM covalent).

Gout-specific data: None found. CBD has not been tested in MSU crystal-induced inflammation models in published literature. The mechanistic basis exists (P2X7 → K+ efflux → NLRP3), but the gout application is mechanistic extrapolation.

Oral bioavailability and GI pharmacokinetics:

  • Absolute oral bioavailability: ~6% fasting; 4–17× higher with a high-fat meal (geometric mean Cmax ratio = 17.4 fed vs. fasting; AUC ratio = 9.7) (Scientific Reports 2025).
  • 70–75% of absorbed dose undergoes hepatic first-pass metabolism before systemic circulation (CNS Drugs 2020).
  • Micellarization in intestinal fluid (fed state): 14.15% (10 mg CBD) and 22.67% (100 mg CBD). Fasted state: 0.65% and 0.14% respectively.
  • GI concentration question answered: The low systemic bioavailability does NOT automatically mean high luminal concentration. The majority of unabsorbed CBD is likely degraded in the colon, not retained as active drug in the gut lumen. The "poor bioavailability = gut-lumen concentration" hypothesis is not supported by available PK data. If gut-lumen anti-inflammatory activity is the goal, this is not the right PK profile.

Open questions remaining: - Does CBD's P2X7 inhibition in the gut specifically suppress MSU-relevant inflammasome signaling in gut-associated macrophages? - Any interaction between CBD and the enteric nervous system's inflammasome regulation?

THC (Delta-9-Tetrahydrocannabinol)

THC activates CB1/CB2 receptors. CB2 activation is anti-inflammatory in multiple immune cell types.

Relevance: - CB2 agonism suppresses NF-κB and downstream IL-1β in some models (CP1) - CB2 is expressed on macrophages, neutrophils, and gut-associated lymphoid tissue - Psychoactivity and regulatory status make THC a poor candidate for a daily supplement stack, but the CB2 mechanism is the mechanistic basis for evaluating beta-caryophyllene and THCV

Verdict: THC is not a practical stack candidate. The CB2-mediated anti-inflammatory pathway it engages is better pursued via non-psychoactive CB2 agonists (beta-caryophyllene, THCV). THC's regulatory status eliminates it from consideration for a food-grade platform regardless of mechanism.

CBG (Cannabigerol)

CBG is the biosynthetic precursor to both CBD and THC. Non-psychoactive. Has newer animal model data that is relevant.

NLRP3 evidence — yes, direct:

  • Animal model (collagen-induced arthritis in rats, 2025): CBG reduced NLRP3 expression in blood and synovial tissue. Also significantly reduced NLRP1A, caspase-1, and gasdermin D (pyroptosis marker). Model: collagen-induced arthritis (CIA), not MSU/gout (Front Pharmacol 2025;16:1705962, PMID: 41230096).
  • In vitro (RAW 264.7 macrophages): CBG anti-inflammatory effects via MAPK and NF-κB pathway inhibition; no cytotoxicity up to 15 μM (J Microbiol Biotechnol 2025, PMID: 41423277).

PPARγ agonism — quantified (and weak):

CBG is a partial PPARγ agonist with higher affinity than CBD or THC at that receptor, but the absolute affinity is modest: - EC50 for PPARγ activation: 1,270–15,700 nM - Ki for PPARγ: ~11.7 μM

At physiologically achievable oral concentrations, PPARγ activation by CBG is likely minimal. The PPARγ → NLRP3 suppression connection exists (ligand-dependent transrepression of NF-κB and inflammasome), but CBG-specific PPARγ → NLRP3 data has not been published. This remains mechanistic extrapolation.

IBD/gut inflammation evidence:

  • Borrelli et al. 2013 (murine DNBS-induced colitis, animal model): CBG reduced colon MPO activity, iNOS expression; increased SOD activity; normalized IL-1β, IL-10, IFN-γ. CB2 receptor antagonism enhanced the anti-inflammatory effect, suggesting the CBG mechanism is partially CB2-independent (Biochem Pharmacol 2013, PMID: 23415610).
  • 2024 (DSS-induced colitis, animal model): High-CBG hemp extract reduced colitis severity scores, improved colon length, reduced colonic damage, and modulated microbiome (J Pharmacol Exp Ther 2024, PMID: 38974519).

Strategic position: CBG has the most relevant gut data of any minor cannabinoid for the EPI/barrier goal. The CIA arthritis NLRP3 data is encouraging but not gout-specific. PPARγ agonism is too weak at achievable concentrations to be the primary mechanism. The NF-κB/MAPK pathway inhibition appears to be the dominant anti-inflammatory mechanism.

CBC (Cannabichromene)

CBC is a non-psychoactive cannabinoid with newer in vitro NLRP3 data and potent TRP channel activity.

NLRP3 inhibition evidence:

  • In vitro (THP-1 macrophages, LPS+ATP stimulation): CBC dose-dependently suppressed pro-IL-1β and mature IL-1β. Lower doses particularly effective at suppressing the second phase (activation) of the inflammasome. Mechanism: mitigates the PANX1/P2X7 axis and downregulates IL-6/TYK2/STAT3 pathway (Molecules 2023;28(18):6487, PMID: 37764262). No formal IC50 reported.

TRP channel activity — strongest among cannabinoids:

  • TRPA1: EC50 = 90 nM for activation; desensitization IC50 = 370 nM. Very potent.
  • TRPV4: EC50 = 600 nM; desensitization IC50 = 9.9 μM
  • TRPV3: EC50 = 1.9 μM
  • In vivo relevance: Inhaled CBC reduced cytokine production in acute respiratory distress models via TRPA1/TRPV1 mechanisms (J Cannabis Res 2021, PMID: 34598736).

NLRP3 priming link via TRP channels: TRPA1 and TRPV1 activation can increase intracellular calcium and ROS, which are NLRP3 priming signals. However, this would be a priming ACTIVATOR, not an inhibitor — the TRP activation data cuts the opposite direction from anti-inflammatory intent. CBC's NLRP3 suppression (via PANX1/P2X7 in macrophages) appears to operate separately from its TRP channel pharmacology. The two effects are not in conflict but are mechanistically distinct.

GI data: No pure CBC GI inflammation studies found.

Strategic position: Primarily a mechanistic reference point. The PANX1/P2X7 mechanism overlaps with CBD's mechanism. Not a priority for the stack given no gout data and regulatory/sourcing complexity.

THCV (Tetrahydrocannabivarin)

THCV has stronger CB2 affinity than beta-caryophyllene and new NLRP3 data.

NLRP3 inhibition evidence:

  • In vitro (THP-1 macrophages, LPS+ATP): THCV at 5 and 15 μM suppressed both pro-IL-1β and mature IL-1β. Suppressed the IL-1β/Pro-IL-1β ratio (marker of activation phase). Mechanism: PANX1/P2X7 axis blockade and NF-κB suppression (Molecules 2023;28(18):6487, PMID: 37764262).

CB1/CB2 receptor profile — notable:

  • CB1: High-affinity antagonist at low/moderate doses (Ki = 75.4 nM); shifts toward partial agonism at high in vivo doses
  • CB2: High-affinity partial agonist (Ki = 7.5 nM; 95% CI: 5.7–10.0 nM) — notably higher CB2 affinity than beta-caryophyllene (CB2 Ki ~155 nM)
  • IC50 for CB1 antagonism: 52.4 nM (Δ9-THCV) and 119.6 nM (Δ8-THCV) vs. CP55,940

(Br J Pharmacol 2007;157(7):1048-1062 and 2008;153(2):199-215)

No gout or uric acid data found. THCV has not been tested in MSU crystal models or for effects on uric acid metabolism.

Regulatory status: THCV is psychoactive at high doses (CB1 agonism threshold) and is derived from cannabis. Sourcing and regulatory status are more complex than beta-caryophyllene. The high CB2 affinity is theoretically attractive, but beta-caryophyllene has direct gout animal model evidence that THCV lacks.

Open question: Would THCV's higher CB2 affinity (Ki 7.5 nM vs. beta-caryophyllene 155 nM) translate to better anti-inflammatory efficacy in gout models? This is testable but unpublished.

2. Terpenes with Anti-Inflammatory Properties

Beta-Caryophyllene — UPGRADED: Direct Gout Animal Model Data

The inhibitor screen classified beta-caryophyllene as Tier 4 with "no gout evidence." That was incorrect — a 2021 paper demonstrates direct efficacy in an MSU gout animal model.

Key findings in MSU-induced gouty arthritis (animal model):

  • Model: MSU crystal injection into rat ankle joints (standard gout flare model)
  • Doses: 100, 200, 400 mg/kg (single daily oral dose)
  • Results: Significant, dose-dependent reduction in:
  • Ankle joint swelling and locomotor dysfunction
  • Serum IL-1β, IL-6, TNF-α
  • Synovial tissue NLRP3, caspase-1, ASC expression
  • TLR4, MyD88, p65 (NF-κB) expression in synovial tissue
  • Computational docking: CDOCKER interaction energy = 31.92 kcal/mol (suggests NLRP3 direct binding; no formal IC50)
  • Evidence level: Animal model (in vivo, MSU-induced gouty arthritis in rats)
  • Citation: Front Pharmacol 2021;12:651305. PMID: 33967792

This is the only terpene or cannabinoid with direct, published data in the gout-specific MSU crystal model.

CB2 agonism — receptor affinity data:

  • CB2 Ki: 155 ± 4 nM (selective CB2 agonist, full agonist functionally)
  • Functional CB2 EC50: ~38 nM (cAMP assay in CHO-K1 cells) to 1.9 μM (depending on assay)
  • CB1 affinity: negligible (selectivity for CB2 over CB1 estimated at >100-fold)

Neutrophil effects — CB2 and NETosis correction:

The stub speculated that CB2 agonism would reduce NET (neutrophil extracellular trap) formation. This is incorrect based on available data:

  • CB2 agonism (JWH133) shows no effect on NETosis in published studies
  • CB1 agonists actually promote NET formation
  • Beta-caryophyllene's neutrophil suppression acts through inhibiting migration/recruitment (via CB2-mediated chemokine reduction: CXCL1/KC, LTB4) rather than NETosis suppression (Inflammopharmacology 2016;24(6):307-318, PMID: 27379721)
  • In the BCG infection model: 50 mg/kg beta-caryophyllene impaired neutrophil recruitment and reduced NO production

Production and practical note: Beta-caryophyllene is a food additive (GRAS, FDA-approved), present in black pepper, cloves, and hops. Oral supplementation with standardized extracts is feasible and legal. Engineered microbial production has low titers and volatility challenges — supplementation is the near-term path, not biosynthesis.

Strategic reassessment: Given the direct MSU gout model data, beta-caryophyllene should be promoted from Tier 4 in the inhibitor screen to Tier 2-3 for gout relevance. It hits CP1 (NF-κB via TLR4/MyD88) and CP2 (NLRP3 assembly), has gout-specific animal evidence, GRAS status, and is readily available. The production challenge remains, but for supplementation (not microbial production), it's a serious candidate.

Dose-translation caveat (flagged 2026-04-26, source: supplements-stack.md): The 2021 MSU rat gout efficacy was demonstrated at 100–400 mg/kg oral. BSA-scaled to a 70 kg human, that is ~1.1–4.5 g/day — 20–50× above the typical supplement dose of 50–200 mg/day. Whether 50–200 mg/day reproduces the synovial NLRP3/TLR4/NF-κB suppression seen in rats is unverified. Treat this entry as "plausible mechanism, dose adequacy unconfirmed" until a PK/PD translation check or human bioavailability study resolves the gap. The orthogonal CB2 mechanism still makes BCP a reasonable low-risk addition; just do not assume the rat dose-response translates to supplement-range doses. (source: supplements-stack.md)

Limonene — PROMOTED to Tier 3 Supplement (2026-04-26)

Status update (source: supplements-stack.md, 2026-04-26): Limonene has been promoted from "not practical" to a Tier 3 supplement candidate based on direct rat MSU gout model data published in 2025.

Mechanism: Nrf2 activator + TLR4 suppression (upstream NLRP3 priming block); suppresses NF-κB, NLRP3, ASC, caspase-1 expression via NRF2-dependent pathway. Hits CP1 (NF-κB/TLR4) and CP2 (NLRP3 assembly).

Gout-specific evidence (PROMOTED, 2026-04-26): Direct rat PO+MSU dual gout model — Venkatesan 2025 Nutrients (PMID 41515190): 50 mg/kg limonene reduced paw thickness, serum UA, IL-1β/TNF/IL-6, and improved antioxidant status; authors invoke NLRP3-IL-1β suppression as the mechanistic frame. (Animal Model; source: supplements-stack.md)

Practical form: d-limonene softgel capsules (commonly sold for GERD / digestive support). Supplement capsule is the practical path — engineered microbial production remains infeasible (<20 mg/L titers + volatility).

Dosing range: 500–1,000 mg d-limonene/day (standardized capsules).

Contraindications: None absolute. Citrus allergy (rare; d-limonene is the dominant terpene in citrus peel). GERD patients: d-limonene is marketed for GERD support but can transiently worsen reflux in a subset (paradoxical LES relaxation). Pregnancy: insufficient supplement-dose data; food-level intake fine.

Drug interactions: - CYP3A4 substrates (statins, calcium channel blockers, immunosuppressants): d-limonene weakly induces CYP3A4 at chronic doses; clinical significance is small at the gout-relevant range. - Acid-suppression drugs (PPIs, H2 blockers): mechanistic overlap with GERD use; not a pharmacological conflict.

Dose-dependent risk profile: - 500–1,000 mg/day: well-tolerated. GRAS food-additive compound at much higher cumulative dietary exposure (orange peel, citrus oils in foods). - >2 g/day chronic: case reports of mild hepatic enzyme elevation (rare; idiosyncratic). - Inhalation/vaporized forms have very different PK and are not appropriate for NLRP3/gout endpoint use.

Stack interactions (within the catalog): - Synergy with sulforaphane, oridonin (Nrf2 axis): cumulative Nrf2 induction with diminishing returns. - No ABCG2 interaction documented.

Cost: $15–25/month

Engineered production: Very low titers (~5–20 mg/L); volatility is the critical barrier. Supplement capsule is the practical path; microbial production is not a near-term target.

Prior verdict revised: The prior "Not practical for oral supplementation" framing was based on the absence of gout-specific data and poor inhalation pharmacokinetics. The Venkatesan 2025 MSU rat model data changes the evidence base for oral supplementation specifically. Microbial production remains impractical; oral d-limonene capsules are a viable Tier 3 supplement addition. (source: supplements-stack.md)

Myrcene

Myrcene has meaningful analgesic and anti-inflammatory data in arthritis models, but no direct NLRP3 assays.

Arthritis model data (animal model, in vivo):

  • Model: Adjuvant monoarthritis in rats (knee joint)
  • Doses: 1 and 5 mg/kg (local sc injection)
  • Acute pain (120 min): 1 mg/kg improved nociception by 211.0 ± 17.93%; 5 mg/kg by 269.3 ± 63.27%
  • Chronic dosing (days 1–21): Sustained reduction in joint pain and inflammatory scores
  • Receptor mechanism: Analgesic effect blocked by both CB1 antagonist (AM281) and CB2 antagonist (AM630); anti-inflammatory effect (leukocyte rolling) blocked by CB2 antagonist only — suggesting dual CB1+CB2 involvement for pain, CB2 primarily for inflammation
  • Anti-inflammatory markers: Reduced leukocyte rolling (early phase); reduced adhesion and vasodilation (chronic)
  • Citation: Int J Mol Sci 2022;23(14):7891. PMID: 35887239

Analgesic mechanism:

Partially opioid-dependent (naloxone-reversible component), but primarily via: - CB1/CB2 receptor engagement (dominant mechanism in arthritis model) - TRPV1 activation (Ca2+ influx-mediated analgesia) - COX/PGE2 inhibition (comparable to indomethacin for PGE2 reduction) - Mechanism: endogenous opioid release via alpha-2-adrenergic stimulation — myrcene does not bind opioid receptors directly

NLRP3 data: None found. The COX/PG inhibition and CB2-mediated leukocyte suppression indirectly reduce NLRP3 priming signals, but myrcene has not been tested in NLRP3-specific macrophage assays. This is mechanistic extrapolation.

Gout-specific relevance: The arthritis model is adjuvant-induced, not MSU crystal-induced. The CB2-mediated leukocyte recruitment suppression is mechanistically relevant to gout (neutrophil influx is a key amplifier of MSU flares), but no MSU data exists.

Pain management use case: Myrcene's strongest case is analgesic during acute flares — particularly the CB2-mediated neutrophil suppression and the non-opioid pain relief in inflammatory arthritis. This is different from NLRP3 suppression. For chronic prevention, it's weaker than beta-caryophyllene.

Alpha-Pinene

  • Monoterpene; in vitro anti-inflammatory (IL-6, TNF-α suppression in LPS-stimulated macrophages)
  • No NLRP3-specific data; no gout data
  • Volatile monoterpene — same production/delivery challenges as limonene
  • Verdict: Low priority pending direct NLRP3 or gout evidence.

3. Uric Acid Metabolism Connections

Cannabis compounds are not known to directly affect uric acid synthesis (xanthine oxidase) or renal excretion (URAT1/ABCG2). No new evidence found to challenge this.

The speculative renal inflammation angle (CBD/CBG → reduced renal inflammation → improved urate clearance) remains mechanistic extrapolation with no direct evidence. No data on cannabinoid effects on serum urate levels found.

Verdict unchanged: The value of cannabinoids and terpenes for Open Enzyme is in NLRP3/inflammation modulation and gut health, not uric acid metabolism. Don't pursue urate axis unless direct evidence emerges.

4. Synergies with Existing Compounds and Drug Interactions

Where Cannabinoids Add Value to the Current Stack

Current CP coverage from NLRP3 Exploit Map: - CP1 (NF-κB priming): BHB, oridonin, quercetin, KPV - CP2 (NLRP3 assembly): Oridonin (covalent Cys279), BHB - CP3 (ASC speck): BHB, oridonin - CP4 (Gasdermin D): Disulfiram

Cannabinoids/terpenes offer: - CB2 agonism (beta-caryophyllene, THCV): Reduces immune cell activation upstream of NLRP3 priming via TLR4/MyD88 suppression. Beta-caryophyllene in the MSU model hit both TLR4/NF-κB (CP1) and NLRP3/caspase-1 (CP2). CB2-mediated mechanism is mechanistically distinct from oridonin (Cys279) or BHB (K+ efflux) — additive potential. - P2X7 block (CBD, CBC, THCV): P2X7 → K+ efflux is a key NLRP3 activation trigger at CP2. This partially overlaps with BHB's mechanism (BHB also reduces K+ efflux). Adding a P2X7 blocker on top of BHB may have diminishing returns at the same chokepoint. - PPARγ agonism (CBG): Not represented in the current stack, but CBG's PPARγ affinity is modest (EC50 1,270–15,700 nM) and the PPARγ → NLRP3 link is mechanistic extrapolation rather than direct evidence.

Pharmacokinetic Interaction: Quercetin + CBD

Clinically relevant finding: Quercetin inhibits CYP3A4 with IC50 = 1.97 μM and also inhibits intestinal UDP-glucuronosyltransferase at achievable concentrations (Biomolecules 2020, PMID: 32751996). CBD is metabolized primarily by CYP2C19 and CYP3A4. Co-administration of quercetin and CBD would be expected to increase CBD plasma exposure — essentially a grapefruit-juice-like effect.

  • Consequence for stack: If CBD is used alongside quercetin (both potential stack components), CBD dosing should be reduced or monitored for increased effect. This interaction works in CBD's favor for bioavailability, but creates dose uncertainty.
  • Evidence level: In vitro enzyme inhibition; pharmacokinetic inference.

Cannabinoids + BHB

No published data found on CBD, CBG, or beta-caryophyllene combined with BHB. The mechanisms are distinct enough (P2X7 vs. K+ efflux / histone deacetylase inhibition vs. mitochondrial protection) that additive effects are plausible, but no empirical evidence exists.

Cannabinoids + Oridonin

No direct combination studies. CBD (P2X7 upstream) and oridonin (covalent NACHT domain Cys279) operate at different points in the inflammasome assembly sequence. No known antagonistic interactions. Additive or synergistic effects are plausible but untested.

4a. Acute-Flare Topical CBD+THC Protocol (new clinical surface, 2026-05-17)

A specific clinical protocol for acute gout flare that sits atop the mechanism evidence in §1–2: topical 1:1 CBD:THC (high-mg/oz formulation) applied to the affected joint, plus ice cycling. (source: gout-action-guide.md)

Mechanism chain: - CB2 receptor activation on synovial macrophages and infiltrating neutrophils suppresses NLRP3 inflammasome assembly and reduces IL-1β release (CB2 → NLRP3/ASC suppression — same downstream chokepoint CP2 as colchicine, reached via a different receptor; see §1 CBG + §2 beta-caryophyllene for the MSU-model evidence base) - Topical TRPV1 desensitization plus cooling (ice / menthol → TRPM8 agonist) adds thermoreceptor-mediated pain reduction at the site - Beta-caryophyllene (CB2-selective agonist; MSU gout model, §2) and CBG (NLRP3 in CIA model, §1) provide the direct inflammasome-suppression evidence - Ice cycling: 10–15 min ice → apply topical → ice again 30–60 min later

Clinical positioning: - For recurrent-flare patients with significant cumulative steroid burden, this protocol may reduce or replace the need for prednisone dose escalation during a step-down rebound - For more severe presentations or systemic effect, oral or inhaled THC:CBD adds systemic CB1/CB2 activation - Evidence level: In Vitro / Animal Model for the mechanism (see §1 and §2 for per-compound evidence); direct human gout-flare RCT evidence absent; mechanistic + indirect evidence base stands on the per-compound data in this page - Access: Cannabis is jurisdiction-dependent and requires medical-program access in many places

Where it fits in the cannabinoid stack framework (§7): this is a different use case from the chronic NLRP3-suppression stack — acute flare management leveraging CB2's fast-onset neutrophil suppression and TRP-mediated analgesia, not long-term inflammasome priming prevention. The oral chronic-suppression stack (beta-caryophyllene, limonene) and the topical acute-flare stack are complementary rather than alternatives. (source: gout-action-guide.md)

Brian's n=1 observation — four-route layered flare-interrupt (added 2026-05-19)

Subject: Brian (gout-prone, on existing prednisone taper at time of observation).

Trigger: Disc-golf overexertion → prodromal flare rebound. Standard protocol would have been to taper back up on prednisone.

Intervention used instead (layered on top of existing prednisone): - Ice cycling at affected joint - Topical 1:1 CBD:THC applied per §4a protocol above - Inhaled cannabis (whole-flower combustion)

Outcome (subjective, self-reported): - Pain resolved within ~1 hour of intervention onset - No recurrence overnight; slept through the night uninterrupted - Next day: returned to baseline pain level or slightly below - Continued topical use over subsequent days with sustained effect

Mechanism interpretation (Mechanistic Extrapolation): four-route layered convergence on NLRP3 via independent receptor pathways and delivery compartments: - Prednisone → systemic glucocorticoid receptor → NLRP3 / IL-1β / NOS2 / ACOD1 transrepression at CP1+CP2 (per H2 lit scan 2026-05-19 — GR signaling controls MSU-driven inflammasome activation directly per Diaz-Jimenez 2026 PMC12862736, and GR's anti-inflammatory effect is timing-dependent: requires LPS priming first, which the prodromal flare provides) - Topical CBD:THC → local CB2 → CP2 (transdermal local on synovial macrophages) - Inhaled cannabis → systemic CB1/CB2 → CP2 (systemic compartment, distinct from topical) - Ice → TRPM8 nociceptive blunting + tissue temperature drop + cold-induced anti-inflammatory effect (peripheral local)

Epistemic tier: n=1, uncontrolled, single observation, multi-intervention (cannot isolate component contributions). Mechanism-composition story is plausible per the per-arm evidence in §1–4 of this page + the GR-mechanism documentation in nlrp3-exploit-map.md §Glucocorticoid Receptor Signaling, but the n=1 observation is hypothesis-generating, not confirmatory. Reasons it might be misleading: regression to mean, placebo effect, natural flare-rebound resolution timing, prednisone alone sufficient. A prospective n=1 A/B test (consecutive flares treated with prednisone-only vs. four-route protocol) would discriminate; the layered design currently doesn't isolate the cannabinoid arms' marginal contribution.

Why document this as n=1 anyway: the platform's self-experiment protocol epistemic discipline (self-experiment-protocol.md) explicitly accommodates n=1 observations with appropriate tier tags. The discipline is to log them, not skip them — single observations in a flare-prone subject with mechanism-aligned interventions are hypothesis-generating data, not noise. Future flare events in the same subject will compound this baseline; n=1 → n=several is the path to characterizing whether the protocol is durably effective.

Cross-references: gout-action-guide.md §"Combined-route flare protocols" Protocol B (the formalized version of this n=1 observation); nlrp3-exploit-map.md §"Glucocorticoid Receptor (GR) Signaling" (the prednisone arm's mechanism documentation); logs/cortisol-fasting-glucocorticoid-inflammasome-lit-scan-2026-05-19.md (the H2 lit scan that established the GR / NLRP3 / MSU mechanism in vivo).

5. Digestive Health and EPI Relevance

CBG is the strongest gut candidate:

  • Direct in vivo colitis data (Borrelli 2013; Frontiers 2024)
  • Reduces IL-1β, MPO activity, iNOS in gut tissue; modulates microbiome
  • CB2 receptor expressed throughout the enteric nervous system
  • Mechanism appears partly CB2-independent (SR144528 enhancement in Borrelli study suggests additional pathways)

CBD GI pharmacokinetics — revisited:

The poor systemic bioavailability (~6% fasting) does NOT support a "stays in gut lumen" model. The unabsorbed CBD fraction is likely degraded, not retained as active compound. For gut-lumen anti-inflammatory intent, CBD is not mechanistically well-suited compared to a molecule like KPV (which is absorbed intact via PepT1 directly in gut epithelium) or BPC-157.

CB1 motility caution: CB1 agonism (THC, high-dose myrcene) slows gut motility. This is a risk for EPI patients who may already have dysmotility. CB2-selective agonists (beta-caryophyllene, THCV) avoid this concern.

EPI-specific data: None found for any cannabinoid or terpene. The connection remains indirect: if cannabinoids reduce gut inflammation and improve barrier integrity, they could reduce secondary inflammation worsening enzyme deficit symptoms. This is mechanistic extrapolation.

Open questions: - Any interaction between cannabinoids and exogenous pancreatic enzyme supplements (Creon/Zenpep)? No data found. - CBG PPARγ agonism and acinar cell health? No data found.

6. Microbial Production Feasibility

Cannabinoids:

  • Full cannabinoid biosynthesis in S. cerevisiae demonstrated (Luo et al., Nature 2019): galactose → CBGA via AAE, OLS, OAC, CBGAS using cannabis genes. Downstream: THCA, CBDA.
  • Titers: ~1–8 mg/L CBGA in early published work — orders of magnitude below quercetin (20–930 mg/L) or ursolic acid (8.59 g/L).
  • CBG and CBD production via this route is feasible in principle but far from production-ready.

Terpenes:

  • Beta-caryophyllene: Sesquiterpene; producible via mevalonate + STS heterologous expression in S. cerevisiae. Published titers ~10–50 mg/L. Volatility causes product loss during fermentation; requires in situ product recovery.
  • Limonene/monoterpenes: Even lower titers (<20 mg/L); volatility worse than sesquiterpenes.

Verdict: Cannabinoid and terpene biosynthesis in yeast or koji are proof-of-concept, not production platforms. For any near-term stack use, supplementation from hemp extracts (CBD, CBG, CBC) or essential oil concentrates (beta-caryophyllene from black pepper/clove) is the practical path. Engineered production is a longer-term possibility as titers improve — not a near-term engineering priority.

7. Evidence Summary and Revised Stack Position

Potency Hierarchy in Context

Compound NLRP3 Mechanism Evidence Level Gout-Specific? Estimated Potency vs. Quercetin (IC50 ~11 μM)
MCC950 Direct NLRP3 ATP pocket Clinical (Phase 2a) Indirect Cell-free 7.5 nM (Coll 2015); not retrievable in ChEMBL by synonyms (2026-04-23)
Oridonin Covalent Cys279 Preclinical; curated human THP-1 IC50 = 5.18 μM in ChEMBL v34 (Eur J Med Chem 2023) No (no gout model) Cellular IC50 5.18 μM in human cells; 0.5–2 μM in cell-free/mouse kinetic assays
Quercetin ASC / upstream; zero curated direct human NLRP3 in ChEMBL; quercetin's most potent ChEMBL activity is 5-LOX (IC50 = 300 nM, J Med Chem 1991) → LTB4 → neutrophil chemotaxis Animal model (MSU) Yes Benchmark functional (~11 μM); 36× more potent on 5-LOX
Beta-caryophyllene CB2/TLR4/NLRP3/NF-κB Animal model (MSU gout); zero curated direct human NLRP3 bioactivities in ChEMBL (functional/downstream markers only) Yes (functional) Unknown — no direct NLRP3 IC50; CB2 Ki 155 nM
CBD P2X7/NF-κB (upstream, indirect) In vitro (human monocytes) No Active 0.1–10 μM; no formal IC50
CBG NF-κB/MAPK (indirect) Animal model (CIA arthritis) No Unknown
THCV P2X7/NF-κB In vitro No Unknown
CBC PANX1/P2X7 In vitro No Unknown
Myrcene COX/PG, CB2 (no NLRP3 assay) Animal model (adjuvant arthritis) No Not applicable

Revised Stack Positions

Beta-caryophyllene: Promote to serious consideration for the supplement stack. The MSU gout animal model data is the decisive finding — it's the only cannabinoid/terpene with this. Bioavailable as a food additive (black pepper, clove oil) without regulatory complexity. GRAS. Acts at CP1 (NF-κB/TLR4) and CP2 (NLRP3/caspase-1). Additive to oridonin and BHB. For a supplement stack context, beta-caryophyllene is more actionable than CBD.

CBG: Interesting for gut/EPI applications given the colitis data, but does not add significantly to the NLRP3 stack beyond what BHB and oridonin already cover at CP1/CP2. Regulatory/sourcing is more complex than beta-caryophyllene. Track but don't prioritize for gout.

CBD: Functional NLRP3 data exists, but the mechanism (upstream P2X7) overlaps with BHB at CP2. Poor gut-lumen pharmacokinetics undermine the GI rationale. The quercetin + CBD PK interaction (quercetin inhibits CBD's CYP3A4 metabolism) is a real consideration if co-administered. Not a priority addition to the current stack unless head-to-head vs. oridonin in MSU models shows superiority.

THCV: Highest CB2 affinity of any compound reviewed (Ki 7.5 nM), but regulatory complexity (cannabis-derived, psychoactive at high dose) and zero gout data make it a research interest, not a current stack candidate.

Myrcene: The arthritis analgesic data makes it interesting for acute flare pain management (CB2-mediated neutrophil suppression + non-opioid analgesia). Not an NLRP3 suppressor based on current evidence. Different use case than the NLRP3 stack — more of a pain/symptom management tool during flares.

CBC, alpha-pinene, limonene: Low priority. No gout data, no production advantage, mechanisms overlap with better-characterized compounds.

8. Experiments That Would Move the Needle

  1. Beta-caryophyllene dose-response in MSU macrophage assay: The in vivo gout data exists, but an in vitro IC50 for NLRP3 inhibition in MSU-stimulated THP-1 cells would allow direct quantitative comparison to quercetin (functional ~11 μM; 300 nM on 5-LOX) and oridonin (curated human THP-1 IC50 = 5.18 μM, ChEMBL v34). Because beta-caryophyllene has zero curated direct human NLRP3 bioactivities in ChEMBL as of 2026-04-23, this experiment would also generate the first-ever direct-inhibition IC50 (versus a functional IL-1β readout) for the compound. Complexity: Low. Cost: $1,000–1,500. Decides: whether beta-caryophyllene belongs in Tier 1 or Tier 2 of the inhibitor screen. (source: nlrp3-inhibitor-screen.md)

  2. THCV vs. beta-caryophyllene head-to-head in CB2 functional assay: THCV's CB2 Ki (7.5 nM) vs. beta-caryophyllene (155 nM) suggests THCV might be more potent. Does higher CB2 affinity translate to better NLRP3 suppression in macrophages? Testable in a BRET or NF-κB reporter assay. Complexity: Low. Cost: $1,500–2,000.

  3. CBG in MSU crystal model: CBG has CIA arthritis data and colitis data, but no MSU gout model data. Testing CBG at 10–50 mg/kg in the MSU rat model would close the most important data gap for this compound. Complexity: Medium. Cost: $3,000–4,000.

  4. Quercetin + CBD PK interaction in rats: If quercetin's CYP3A4 inhibition (IC50 = 1.97 μM) meaningfully increases CBD plasma exposure, that could actually improve CBD's NLRP3 efficacy when the two are co-administered. Measurable as a simple pharmacokinetics study. Complexity: Medium. Cost: $2,000–3,000.

  5. Beta-caryophyllene + oridonin combination in MSU model: Both hit CP1 and CP2 via different mechanisms (CB2/NF-κB vs. covalent Cys279). Combination might allow dose reduction of oridonin (reducing hepatic risk from any off-target effects). Complexity: Medium. Cost: $3,000–5,000.